| Study Period | 2021 - 2030 |
| Market Size (2025) | USD 3.20 Billion |
| Market Size (2030) | USD 4.83 Billion |
| CAGR (2025 - 2030) | 8.55 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Breast Cancer Screening Test Market Analysis
The Global Breast Cancer Screening Test Market size is estimated at USD 3.20 billion in 2025, and is expected to reach USD 4.83 billion by 2030, at a CAGR of 8.55% during the forecast period (2025-2030).
The breast cancer screening industry is undergoing significant technological transformation, particularly in artificial intelligence and advanced imaging capabilities. The integration of AI-powered solutions has revolutionized screening accuracy and efficiency, as evidenced by the Radiological Society of North America's launch of the RSNA Screening Mammography Breast Cancer Detection AI Challenge in late 2023. This technological evolution has been accompanied by breakthrough developments in ultrasound technology, exemplified by the Barcelona Supercomputing Center's QUStom project, which aims to replace traditional X-ray-based mammography with advanced ultrasound imaging combined with supercomputing capabilities.
Healthcare infrastructure development continues to shape the breast cancer diagnostics market landscape, with significant investments in screening facilities and mobile units. In January 2023, the UK government demonstrated this trend by awarding over £1.6 million in funding to Nottingham University Hospitals Trust for expanding breast cancer screening capabilities, including the deployment of two new mobile screening units. This infrastructure expansion reflects a broader industry trend toward improving accessibility and reducing geographical barriers to screening services, particularly in underserved areas.
The research and innovation landscape has witnessed remarkable advancement in diagnostic accuracy and patient comfort. According to recent statistics from Breastcancer.org, the United States alone expects to diagnose approximately 287,850 new cases of invasive breast cancer, alongside 51,400 new cases of non-invasive breast cancer, highlighting the critical need for continued innovation in screening technologies. The industry has responded with significant developments in non-invasive breast cancer screening test methods and more accurate diagnostic tools, particularly in digital breast tomosynthesis and molecular imaging.
Strategic collaborations and technological certifications have become increasingly prominent in shaping market dynamics. A notable development in this direction was Hologic's 3Dimensions mammography system receiving EUREF Type Test certification from the European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services, establishing new benchmarks for digital breast tomosynthesis systems. These certifications and partnerships have fostered standardization in screening protocols while promoting the adoption of advanced screening technologies across healthcare institutions globally.
Breast Cancer Screening Test Market Trends
Increasing Awareness About Early Detection of Breast Cancer
The rising awareness about early breast cancer detection tests through various campaigns and initiatives is playing a crucial role in driving market growth. Healthcare organizations, non-profits, and government bodies are actively conducting awareness programs to educate people about breast cancer and promote early breast cancer screening protocols. For instance, in January 2023, the UK government granted an additional GBP 10 million to deliver 29 new breast cancer screening units, including 16 new mobile breast screening units and 13 new static units, demonstrating the commitment to improving screening accessibility. These initiatives are complemented by technological advancements like the integration of AI-driven breast software tools that improve mammography quality, reporting, and volumetric breast density measurements.
The implementation of comprehensive awareness programs has led to increased participation in screening activities across different regions. For example, in 2023, VNA Health Care launched its 'Worth the Squeeze' Initiative, aimed at helping women understand the importance of regular mammograms and early detection. Additionally, organizations like AstraZeneca Singapore have signed Memorandums of Understanding with the Breast Cancer Foundation to improve overall breast cancer awareness and detection rates. These collaborative efforts between healthcare providers, government bodies, and non-profit organizations are creating a robust ecosystem for breast cancer screening awareness, ultimately driving the adoption of screening tests.
Understand The Key Trends Shaping This Market
Download PDF
Growing Incidence of Breast Cancer
The escalating incidence of breast cancer globally has become a significant driver for the breast screening test market. According to the American Cancer Society's 2023 report, approximately 300,590 new breast cancer cases are predicted to occur in the United States alone, accounting for 30% of all new cancer cases in women. This substantial disease burden has created an urgent need for effective breast cancer screening programs and early detection methods. The rising prevalence is attributed to various factors, including lifestyle changes, hormonal factors, and environmental influences, all of which contribute to the increasing demand for breast cancer screening tests.
The growing incidence rates have prompted healthcare systems worldwide to strengthen their screening capabilities. For instance, according to recent statistics from Breast Cancer Now, approximately 55,000 women are diagnosed with breast cancer annually in the United Kingdom, with 46,000 cases in England, 4,700 in Scotland, 2,800 in Wales, and 1,500 in Northern Ireland. These high incidence rates have led to the implementation of more robust screening programs and the adoption of advanced screening technologies, such as 3D mammography and AI-enabled detection systems, to improve early diagnosis rates and treatment outcomes.
Increasing Government Initiatives and Support
Government initiatives and support mechanisms have emerged as a crucial driver for the breast screening test market, with numerous countries implementing comprehensive screening programs and financial support systems. In 2023, significant investments have been made in screening infrastructure and technology. For example, NHS England received an additional GBP 10 million to deliver new breast cancer screening units, demonstrating the government's commitment to expanding screening accessibility. These initiatives include the deployment of advanced imaging tools, software upgrades for ultrasounds and X-rays, and the establishment of mobile screening units to reach underserved populations.
The support extends beyond financial assistance to include policy frameworks and screening guidelines. For instance, in May 2023, the U.S. Department of Health and Human Services has been actively working to increase equitable access to life-saving cancer screening tests for females through community health centers. Additionally, government healthcare organizations are implementing initiatives to provide women between the ages of 50 and 75 access to mammography and other screening tests. The European Union's new approach aims to support Member States in ensuring that 90% of the EU population who qualify for breast cancer screenings will be offered such screening by 2025, showcasing the comprehensive nature of government support in driving market growth.
Segment Analysis: By Test
Imaging Tests Segment in Breast Cancer Screening Test Market
The Imaging Tests segment dominates the global breast cancer screening tests market, commanding approximately 76% market share in 2024. This segment encompasses various imaging technologies, including mammograms, ultrasound, MRI, tomography, and other imaging tests, with mammography being the most widely utilized screening method. The segment's prominence is driven by increasing government initiatives for breast cancer test programs worldwide, technological advancements in imaging modalities, and the growing adoption of 3D mammography and AI-enabled imaging solutions. The segment is also experiencing the fastest growth trajectory, projected to grow at around 9% from 2024 to 2029, fueled by continuous innovations in imaging technologies, increasing awareness about early detection, and expanding healthcare infrastructure in developing regions. Major market players like Hologic, GE Healthcare, and Siemens Healthineers are actively developing advanced imaging solutions, incorporating artificial intelligence and machine learning capabilities to improve diagnostic accuracy and efficiency in the breast cancer imaging market.
Genomic Tests Segment in Breast Cancer Screening Test Market
The Genomic Tests segment represents a crucial component of the cancer testing screening market, accounting for nearly 24% of the market share in 2024. This segment has gained significant traction due to its ability to provide detailed genetic information for personalized treatment approaches and risk assessment. The increasing adoption of next-generation sequencing technologies, growing awareness about genetic testing, and rising demand for precision medicine are driving the segment's growth. Companies like Myriad Genetics and NanoString Technologies are at the forefront of developing innovative genomic testing solutions, offering comprehensive genetic panels and molecular diagnostic tests for breast cancer test screening. The segment's growth is further supported by increasing research and development activities, expanding applications in early detection, and growing acceptance of genetic testing among healthcare providers and patients.
Global Breast Cancer Screening Test Market Geography Segment Analysis
Breast Cancer Screening Test Market in North America
North America represents a highly developed breast cancer screening market, characterized by advanced healthcare infrastructure and widespread adoption of screening programs. The region benefits from strong government support, comprehensive insurance coverage, and high awareness levels about early cancer detection. The United States, Canada, and Mexico comprise this market, with each country having distinct healthcare systems and screening protocols. The presence of major market players and continuous technological advancements in screening methodologies further strengthen the regional market dynamics.
Breast Cancer Screening Test Market in the United States
The United States dominates the North American breast cancer screening test market, holding approximately 84% of the regional market share. The country's leadership position is attributed to its robust healthcare infrastructure, extensive screening programs, and strong presence of key industry players. The market is driven by comprehensive insurance coverage, including Medicare and private insurance plans that cover regular mammogram screenings. The country's healthcare system emphasizes preventive care, with various organizations actively promoting breast cancer awareness and early detection programs. The United States also leads in the adoption of advanced screening technologies, including 3D mammography and AI-enabled detection systems.
Breast Cancer Screening Test Market in Mexico
Mexico, while currently having a smaller market share, demonstrates significant growth potential in the cancer screening market with a projected CAGR of approximately 7% from 2024-2029. The country is witnessing increasing healthcare expenditure and growing awareness about breast cancer screening. The Mexican government's initiatives to improve healthcare infrastructure and expand access to screening services are contributing to market growth. Private sector investments in advanced screening technologies and increasing partnerships between international medical device companies and local healthcare providers are further driving market expansion. The country's focus on preventive healthcare and rising disposable income levels are expected to sustain this growth trajectory.
Breast Cancer Screening Test Market in Europe
The Europe breast cancer screening market demonstrates a sophisticated landscape with well-established screening programs across different countries. The region benefits from strong healthcare policies, advanced medical infrastructure, and high awareness levels about breast cancer prevention. Key markets include Germany, the United Kingdom, France, Italy, and Spain, each with its unique healthcare systems and screening protocols. The European Union's initiatives for standardized screening guidelines and quality assurance programs further strengthen the market framework.
Breast Cancer Screening Test Market in Germany
Germany leads the European breast cancer screening test market, commanding approximately 22% of the regional market share. The country's market leadership is supported by its comprehensive healthcare system, advanced medical infrastructure, and strong research capabilities. German healthcare policies emphasize preventive care, with nationwide mammography screening programs available to all eligible women. The presence of major medical device manufacturers and continuous investments in healthcare technology innovation further solidifies Germany's position in the market.
Breast Cancer Screening Test Market in Germany - Growth Analysis
Germany also emerges as the fastest-growing market in Europe, with a projected CAGR of approximately 10% from 2024-2029. This growth is driven by increasing adoption of advanced screening technologies, strong research and development activities, and continuous healthcare system improvements. The country's focus on integrating artificial intelligence and digital solutions in breast cancer screening, coupled with rising investments in healthcare infrastructure, supports this growth trajectory. German healthcare providers' emphasis on early detection and preventive care continues to drive market expansion.
Breast Cancer Screening Test Market in Asia-Pacific
The Asia breast cancer screening market represents a dynamic and rapidly evolving landscape with significant growth potential. The region encompasses diverse healthcare systems across countries including China, Japan, India, Australia, and South Korea. Each market demonstrates unique characteristics in terms of healthcare infrastructure, screening programs, and technology adoption rates. The region's large population base and increasing awareness about early cancer detection create substantial market opportunities.
Breast Cancer Screening Test Market in China
China emerges as the largest market in the Asia-Pacific region, driven by its extensive population base and expanding healthcare infrastructure. The country's focus on modernizing healthcare facilities and increasing access to screening services supports its market leadership. Government initiatives promoting early cancer detection, coupled with rising healthcare expenditure and growing awareness about breast cancer screening, contribute to China's dominant position in the regional market.
Breast Cancer Screening Test Market in Japan
Japan demonstrates the fastest growth trajectory in the Asia-Pacific region, supported by its advanced healthcare system and strong technological capabilities. The country's emphasis on preventive healthcare, coupled with high adoption rates of innovative screening technologies, drives market expansion. Japanese healthcare providers' focus on precision medicine and personalized screening approaches, along with government support for cancer prevention programs, contributes to this growth momentum.
Breast Cancer Screening Test Market in Middle East & Africa
The Middle East & Africa breast cancer screening test market shows promising growth potential, characterized by increasing healthcare investments and rising awareness about early cancer detection. The region, comprising GCC countries and South Africa, demonstrates varying levels of healthcare infrastructure and screening program implementation. Within this region, GCC countries lead the market size while South Africa shows the fastest growth rate, driven by improving healthcare access and increasing government initiatives for cancer screening programs.
Breast Cancer Screening Test Market in South America
The South American breast cancer screening test market is characterized by growing healthcare awareness and improving access to screening services. The region, primarily represented by Brazil and Argentina, shows increasing adoption of advanced screening technologies and expanding healthcare infrastructure. Brazil emerges as both the largest and fastest-growing market in the region, supported by its large population base, improving healthcare systems, and increasing government focus on cancer prevention programs.
Get Analysis on Important Geographic Markets
Download PDF
Breast Cancer Screening Test Industry Overview
Top Companies in Breast Cancer Screening Test Market
The breast cancer screening tests market features prominent players like F. Hoffmann-La Roche, Myriad Genetics, Koninklijke Philips, GE Healthcare, Fujifilm Holdings, and Hologic Inc. These companies are actively pursuing product innovation through advanced imaging technologies, particularly in mammography systems and AI-enabled diagnostic tools. Strategic partnerships with healthcare providers and research institutions have become increasingly common to enhance screening capabilities and market reach. Companies are expanding their geographical presence through both organic growth and acquisitions, with a particular focus on emerging markets in Asia-Pacific and Latin America. The industry demonstrates strong investment in research and development, especially in areas like 3D tomosynthesis, AI-based detection systems, and portable screening devices, while also emphasizing the development of comprehensive screening solutions that combine multiple diagnostic modalities.
Consolidated Market with Strong Regional Leaders
The breast cancer diagnostic technologies market exhibits a relatively consolidated structure dominated by large multinational healthcare conglomerates with diverse product portfolios spanning diagnostic imaging, healthcare IT, and clinical solutions. These established players leverage their extensive distribution networks, strong brand recognition, and significant research capabilities to maintain their market positions. Regional markets often feature strong local players who compete effectively through their understanding of local healthcare systems and established relationships with healthcare providers. The market has witnessed significant merger and acquisition activity, particularly involving smaller innovative companies with promising technological capabilities being acquired by larger corporations seeking to enhance their screening portfolios.
The competitive dynamics are characterized by a mix of global medical device manufacturers and specialized diagnostic companies, with the former typically offering comprehensive healthcare solutions while the latter focus on specific screening technologies or diagnostic approaches. Market consolidation continues through strategic partnerships and joint ventures, particularly in developing regions where companies seek to establish a stronger market presence. The industry demonstrates high barriers to entry due to stringent regulatory requirements, substantial capital requirements for research and development, and the need for extensive clinical validation of screening technologies.
Innovation and Integration Drive Market Success
Success in the breast cancer imaging diagnostic equipment market increasingly depends on companies' ability to develop integrated screening solutions that combine multiple diagnostic modalities with artificial intelligence and data analytics capabilities. Incumbent players must focus on continuous innovation in imaging technology, workflow optimization, and cost-effectiveness while maintaining strong relationships with healthcare providers and regulatory bodies. The ability to offer comprehensive screening programs, including both hardware and software solutions, along with robust after-sales support and training, has become crucial for maintaining market share. Companies must also address the growing demand for mobile and portable screening solutions while ensuring compliance with evolving healthcare regulations and reimbursement policies.
For emerging players and market contenders, success lies in identifying and exploiting specific market niches or technological gaps in the current screening landscape. This includes developing specialized screening solutions for specific patient populations or healthcare settings, leveraging new technologies like AI and machine learning, and forming strategic partnerships with established healthcare providers. Companies must navigate complex regulatory environments while demonstrating clear clinical benefits and cost advantages of their screening solutions. The increasing focus on personalized medicine and early detection creates opportunities for innovative approaches to breast cancer screening, though success requires careful consideration of healthcare provider preferences, patient acceptance, and integration with existing screening protocols.
Breast Cancer Screening Test Market Leaders
-
Siemens Healthineers
-
Hologic Inc.
-
General Electric Company
-
Koninklijke Philips NV
-
Fujifilm Holdings
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Breast Cancer Screening Test Market News
- In June 2022, Biomerica, Inc. entered a general merchandise supplier agreement with Walmart. The Aware Breast Self Exam device will be sold in Walmart's retail system.
- In March 2022, LifeCelllaunched Breast Screen Panel, a comprehensive genetic screening test that assesses the risk of breast cancer in women.
Breast Cancer Screening Test Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Awareness about Early Detection of Breast Cancer
- 4.2.2 Growing Incidence of Breast Cancer
- 4.2.3 Increasing Government Initiatives and Support
-
4.3 Market Restraints
- 4.3.1 Controversies Related to Mammography
- 4.3.2 High Cost of Screening Tests in the Developing Countries
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Test
- 5.1.1 Genomic Tests
- 5.1.2 Imaging Test
- 5.1.2.1 Mammograms
- 5.1.2.2 Ultrasound
- 5.1.2.3 MRI
- 5.1.2.4 Tomography
- 5.1.2.5 Other Imaging Tests
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kindgom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Middle East & Africa
- 5.2.4.1 GCC
- 5.2.4.2 South Africa
- 5.2.4.3 Rest of Middle East & Africa
- 5.2.5 South America
- 5.2.5.1 Brazil
- 5.2.5.2 Argentina
- 5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 F. Hoffmann-La Roche Ltd
- 6.1.2 Myriad Genetics, Inc.
- 6.1.3 Koninklijke Philips N.V.
- 6.1.4 Carestream Health
- 6.1.5 GE Healthcare
- 6.1.6 Fujifilm Holdings Corporation
- 6.1.7 NanoString Technologies, Inc.
- 6.1.8 Siemens Healthineers
- 6.1.9 Hologic Inc.
- 6.1.10 Quest Diagnostics Incorporated
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now
Breast Cancer Screening Test Industry Segmentation
As per the scope, breast cancer screening is carried out to detect cancer early and ensure timely treatment for the patients. Different types of breast cancer depend on the type of cancer cell that becomes cancerous. Breast cancer can affect different parts of the breast, such as the ducts and the lobes. The Breast Cancer, Screening Test Market, is Segmented by Test (Genomic Tests and Imaging Tests) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
| By Test | Genomic Tests | ||
| Imaging Test | Mammograms | ||
| Ultrasound | |||
| MRI | |||
| Tomography | |||
| Other Imaging Tests | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kindgom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East & Africa | GCC | ||
| South Africa | |||
| Rest of Middle East & Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Breast Cancer Screening Test Market Research FAQs
How big is the Global Breast Cancer Screening Test Market?
The Global Breast Cancer Screening Test Market size is expected to reach USD 3.20 billion in 2025 and grow at a CAGR of 8.55% to reach USD 4.83 billion by 2030.
What is the current Global Breast Cancer Screening Test Market size?
In 2025, the Global Breast Cancer Screening Test Market size is expected to reach USD 3.20 billion.
Who are the key players in Global Breast Cancer Screening Test Market?
Siemens Healthineers, Hologic Inc., General Electric Company, Koninklijke Philips NV and Fujifilm Holdings are the major companies operating in the Global Breast Cancer Screening Test Market.
Which is the fastest growing region in Global Breast Cancer Screening Test Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Breast Cancer Screening Test Market?
In 2025, the North America accounts for the largest market share in Global Breast Cancer Screening Test Market.
What years does this Global Breast Cancer Screening Test Market cover, and what was the market size in 2024?
In 2024, the Global Breast Cancer Screening Test Market size was estimated at USD 2.93 billion. The report covers the Global Breast Cancer Screening Test Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Global Breast Cancer Screening Test Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Global Breast Cancer Screening Test Market Research
Mordor Intelligence provides a comprehensive analysis of the breast cancer screening market, utilizing extensive expertise in healthcare diagnostics research. Our detailed report covers the full range of breast cancer diagnostic technologies and testing methodologies. This includes mammography screening, breast imaging diagnostic equipment, and emerging detection solutions. We focus particularly on key regions such as the Asia breast cancer screening market and the Europe breast cancer screening market. Our analysis extends to significant developments in breast cancer screening tests and their implementation across healthcare systems, with special attention to growing markets like breast cancer in India 2024.
Stakeholders gain invaluable insights through our detailed examination of cancer screening test methodologies and market dynamics. This is available in an easy-to-download report PDF format. The analysis encompasses various aspects of breast cancer detection test procedures, breast screening test protocols, and emerging technologies in cancer early detection and diagnosis. Our report provides comprehensive breast cancer screening statistics and a detailed analysis of breast tumor size metrics. This enables healthcare providers, manufacturers, and investors to make informed decisions about market opportunities and technological advancements in cancer screening tests for females.
